Insmed (INSM) said Friday said it expects to report full-year 2024 global net product sales of its drug Arikayce of $363.7 million, up 19% year over year.
The results are preliminary and subject to adjustment, the company said. Insmed expects to report its actual results in late February.
Analysts polled by FactSet expect $356.8 million in full-year revenue.
Price: 65.21, Change: -0.51, Percent Change: -0.78
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。